- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Clinicopathologic Spectrum of Renal Lesions Following Anti-TNF Alpha Inhibitor Therapy: A Single-Center Experience (Exhibit Hall, Walter E. Washington Convention Center) - Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_4592;
In addition, active or chronic thrombotic microangiopathy was noted in 5, possibly associated to scleroderma or antiphospholipid antibodies, and nephrotic syndrome secondary podocytopathy in 2 cases. Conclusion The renal lesions during anti-TNF alpha therapy may have an autoimmune basis such as lupus, lupus-like or ANCA mediated disease, as well as secondary to endothelial or podocyte injury or related to the primary underlying systemic disease.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Tubulointerstitial Nephritis and Uveitis Unmasked by Decreasing Anti-TNF Alpha (Exhibit Hall, Walter E. Washington Convention Center) - Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_4105;
Case Description 55-year-old Caucasian male with history of hypertension on lisinopril and psoriatic arthritis on adalimumab admitted for acute renal failure...He was also initiated on prednisone for concerns of acute interstitial nephritis...Discussion In patient with TINU, uveitis can present as vision loss without apparent inflammation, and it often presents separately from interstitial nephritis. This patient has atypical posterior uveitis and biopsy-proven AIN consistent with TINU, likely unmasked by tapering of adalimumab.
- |||||||||| Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
Not So Stellar: IgA Nephropathy Secondary to Immunotherapy Treatment for Psoriasis (Exhibit Hall, Walter E. Washington Convention Center) - Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_1766;
He was treated with adalimumab,but became ineffective and it was changed to Ustekinumab...Ustekinumab was discontinued, and he was started on prednisone 60 mg PO daily and losartan 50 mg po daily...Nephrologists should be suspicious of the relationship of this agent and IgAN. It is important to diagnose early to ensure adequate treatment to minimize long term kidney complications.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
IgA Nephropathy in Patients with Psoriatic Arthritis: A Case Series and Systematic Review of the Literature (Exhibit Hall, Walter E. Washington Convention Center) - Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_1739;
She was treated with prednisone and recovered kidney function after 20 days...She was treated with steroids and cyclophosphamide, with improvement to eGFR 22 mL/min...There is heterogeneity in these patients’ presentations, treatments, and outcomes. Conclusion Further study is warranted to determine whether there is a pathophysiological link between IgAN and PsA.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Humira (adalimumab) / Eisai, AbbVie
Tocilizumab-Induced Immune Complex Glomerulonephritis in a Patient with Rheumatoid Arthritis (Exhibit Hall, Walter E. Washington Convention Center) - Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_1506;
Three years ago, the biologic was switched from adalimumab to TCZ...After discontinuing TCZ and MTX, intravenous methylprednisolone was administered at a dose of 500 mg/day for three days and then prednisolone (PSL) was initiated at 60 mg/day...The mechanism remains unknown because only one case of TCZ-induced IC-GN has been reported to date. Rheumatologists and nephrologists should be aware of this lesion and similar cases should be collected in future.
- |||||||||| Journal: Biologic therapies in ulcerative colitis: primi inter pares? (Pubmed Central) - Oct 13, 2019
Other factors, including convenience and satisfaction for the patient, route of administration, the cost of treatment, and the safety and efficacy profile, should all be considered. The aim of this review is to discuss the data from randomized controlled trials (RCTs) of available biological agents for the treatment of moderate-to-severe UC in adults, in order to support clinical decision making.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Journal: Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease. (Pubmed Central) - Oct 12, 2019
Regarding the Lachnospiraceae family, in patients with normalization of C reactive protein six 6 months of adalimumab therapy, it increased from 16.6 ± 3.1% at T0 to 23.9 ± 2.6% at T1 (p = 0.049). In conclusion, in patients who respond to Adalimumab therapy by decreasing inflammation, there is a trend of intestinal eubiosis being restored.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Journal: Sunburn Recall Reaction and Mucositis Secondary to Methotrexate Toxicity. (Pubmed Central) - Oct 10, 2019
Cutaneous examination revealed hemorrhagic crusting of upper and lower lips (Figure 2), scleral icterus, diffuse jaundice of the skin, and well-demarcated erythematous patches on mid-upper back and anterior neck. The patient had a few scattered erythematous papules with whitish center on bilateral extensor surfaces of the upper extremities and scattered petechiae on both the trunk and upper extremities.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion date: OTIS Autoimmune Diseases in Pregnancy Project (clinicaltrials.gov) - Oct 9, 2019
P=N/A, N=554, Active, not recruiting,
This pharmacogenetic analysis identified genetic components that contribute to clinical responses to anti-rheumatic therapy. Trial completion date: Apr 2017 --> Dec 2019
- |||||||||| Journal: Biologic-Induced Infections in Inflammatory Bowel Disease: The TNF-α Antagonists. (Pubmed Central) - Oct 9, 2019
TNF-α antagonists are associated with an increased risk of opportunistic infection, although this risk has not been demonstrated conclusively in randomized controlled trials. Knowledge of concomitant risk factors, mechanism of infectious risk, and available treatment options can improve patient care in the clinical setting.
- |||||||||| Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Biomarker, Journal: Self-adjusting cytokine neutralizer cells as a closed-loop delivery system of anti-inflammatory biologicals. (Pubmed Central) - Oct 8, 2019
Considering the high impact of environmental influences on the dynamics of cell-based systems, we established closed-loop controllable cytokine neutralizer cells, monitoring cytokine levels and autonomously delivering powerful biologicals. This real-time processing system may provide dose-dependent drug delivery, which may be tailored for prospective cell and gene therapies against RA, and may offer a more personalized medicine than calculated drug dosing based on body weight.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Testing Different Thresholds for Patient Global Assessment in Defining ACR-EULAR Boolean Remission Criteria for RA (B312/B314) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3903;
Increasing the PGA cut-off to 1.5cm would provide highest consistency between Boolean with the Index based remission; the integer cut-off of 2.0cm performed similarly and would also allow the use of numerical rating scales. This new cut-off discounts the excessive stringency of the current PGA cut-off in the remission context, while maintaining similar functional and radiographic long-term outcomes.
- |||||||||| Decomposition Analysis of Spending and Price Trends for Biologic Anti-Rheumatic Drugs in Medicare and Medicaid (Hall B1) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3781;
Post-market drug-price changes alone accounted for the majority of recent bDMARD spending growth, and manufacturers’ rebates had little impact on these findings. Beyond rebates, policy interventions that target price increases, particularly under Part D plans, may help mitigate public-payer drug spending and out-of-pocket costs for the elderly and disabled beneficiaries who rely on bDMARDs.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
The Impact of Psoriasis Severity on Outcomes Among Psoriatic Arthritis Patients Receiving Adalimumab (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3658;
Beyond rebates, policy interventions that target price increases, particularly under Part D plans, may help mitigate public-payer drug spending and out-of-pocket costs for the elderly and disabled beneficiaries who rely on bDMARDs. Prevalence of severe PsO in this population of PsA pts was consistent with previous observations.3 Treatment with ADA was associated with better PsA outcomes as compared to PBO irrespective of the degree of PsO severity at baseline.
- |||||||||| Can Biologics “Prevent” the Development of Psoriatic Arthritis in Psoriasis Patients? Data from a Large University Hospital Cohort in Argentina (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3656;
Patients were classified according to their treatment in topics group (topic and phototherapy), conventional DMARDs (cDMARDs) group (Methotrexate (MTX) and cyclosporine (Cyc)), and biologic DMARDs group (bDMARDs) (TNFi, IL17i, and IL12-23i)...599 (75%) patients were treated only with topics or phototherapy, 106 (13%) with cDMARDs (81% MTX and 19% Cyc) and 92 (11.5%) with biologics (TNFi: 64: etanercept: 44, adalimumab:23, infliximab:6 ; IL17i: 43: 14 Ixekizumab, 29 Secukinumab; IL12-23i: (Ustekinumab) 16; some patients received more than one biologic)... Treatment with biologics in patients with PsO seemed to reduce the risk of PsA and preventing its development in this retrospective single center cohort.*This study was achieved with a grant from PANLAR (Pan-American League Against Rheumatism).
- |||||||||| Differences and Similarities According to Gender in Patients with Psoriatic Arthritis Initiating Biological Therapy (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3633;
Nevertheless, the predominant articular manifestation behind the prescription of the biological therapy is different among genders: while men have predominant axial disease, women have predominant peripheral manifestations. These differences in clinical presentation in both genders may contribute to differences in therapeutic management, such as increased use of methotrexate in women with PsA who initiate biological therapy.
- |||||||||| Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Pregnancy in Rheumatoid Arthritis: Continue, Reduce or Stop TNF Inhibitors? A Prospective Observational Study (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3444;
When in remission under ongoing TNFi therapy during pregnancy, it seems possible and safe for women to reduce the frequency of injections in a disease activity guided manner. These real-world data will help to provide women with comprehensive advice on treatment options and risks regarding TNFi therapy at pregnancy counselling.
- |||||||||| Risk of Serious Infections in Offspring According to TNFi Subtypes (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3438;
When we compared the risk of serious infections in offspring exposed to TNFi with high vs low placental transfer, we observed a potential trend for an increased risk, although the CI was wide and included the null value. Our findings stress the need to further study this issue.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Effect of Biologics on the Hemoglobin A1c in a Population of Rheumatoid Arthritis Patients (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3420;
No statistically significant difference in HbA1c levels or glucose control could be determined from initiating biologics in non DMARD-naïve RA patients with or without DM. Further large-scale, prospective studies on the impact of biologic therapy on non-articular outcomes are warranted to assess the need of preferentially starting these medications in the above-mentioned population.
- |||||||||| Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Discontinuation of Disease Modifying Drugs in Patients with Incident Rheumatoid Arthritis (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3399;
The major cause of suspension was adverse event appearance, followed by inefficacy. It seems that discontinuations are more common in combined therapies (especially in triple therapy) and in therapies including biologic drugs.
- |||||||||| Comparison of Healthcare Resource Utilization (HCRU) and Costs of Type 2 Diabetes Mellitus (T2DM)-Related Complications in TNFi-Experienced Medicare Beneficiaries with Rheumatoid Arthritis (RA) and T2DM Who Switch to Abatacept or Other Targeted Disease-Modifying Anti-Rheumatic Drugs (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3395;
In this retrospective cohort study, 100% Medicare fee-for-service (FFS) claims (Parts A/B/D) were used to identify TNFi-experienced RA patients who initiated abatacept, another TNFi (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab) or non-TNFi (anakinra, rituximab, sarilumab, tocilizumab, tofacitinib) from 2010 through 2017. These findings suggest that TNFi-experienced Medicare patients with RA and T2DM who switch to abatacept had a reduction in the rate and cost of hospitalizations associated with T2DM-related complications in comparison to patients who switch to other tDMARDs
|
